Diagnostic Utility of Galectin-3 in Thyroid Cancer

Chiu, Connie G.; Strugnell, Scott S.; Griffith, Obi L.; Jones, Steven J.M.; Gown, Allen M.; Walker, Blair; Nabi, Ivan R.; Wiseman, Sam M.

doi:10.2353/ajpath.2010.090353

Cited by 135 publications

(103 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, increased plasma galectin-3 levels have been reported in (metastasized) cancer [4,5,13,14,[28][29][30]], Behçet's disease [7] and obesity [8], and galectin-3 levels may even guide therapy [14]. We hypothesize that deleterious signals that precede overt disease initiate subclinical tissue changes associated with galectin-3 activation and secretion.…”

Section: Discussionmentioning

confidence: 99%

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

336

291

View full text Add to dashboard Cite

Abstract. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.Objective. Galectin-3 is involved in fibrosis and inflammation and plays a role in heart failure, renal disease, obesity and cancer. We aimed to establish the relationship between galectin-3 and cardiovascular (CV) risk factors and mortality in the general population.Design and subjects. This study included 7968 subjects from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort, with a median follow-up of approximately 10 years. Plasma galectin-3 was measured in baseline samples.Main outcome measures. We investigated the relationships between galectin-3 levels, demographic characteristics and risk factors of CV disease. We determined the prognostic value for all-cause, CV and cancer mortality.Results. The mean age of the population was 50 ± 13 years. Mean blood pressure was 129 ⁄ 74 mmHg, mean cholesterol was 5.7 ± 1.1 mmol L )1 and median galectin-3 was 10.9 ng mL )1 [interquartile range (IQR) 9.0-13.1]. Galectin-3 levels correlated with a wide range of risk factors of CV disease, including blood pressure, serum lipids, body mass index, renal function and N-terminal pro-B-type natriuretic peptide (P < 0.0001). We observed a strong association between galectin-3 and age. Furthermore, we found a gender interaction, with female subjects (n = 4001) having higher median galectin-3 levels (11.0 ng mL )1 , IQR 9.1-13.4 vs. men (n = 3967) 10.7 ng mL )1 , IQR 8.9-12.8; P < 0.0001), and galectin-3 levels in women more strongly correlated with risk factors of CV disease. After correction for the classical CV risk factors (smoking, blood pressure, cholesterol and diabetes), galectin-3 levels independently predicted all-cause mortality (hazard ratio per SD galectin-3 1.09, 95% CI 1.01-1.19; P = 0.036), but not CV and cancer mortality separately.Conclusions. Galectin-3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin-3 predicts all-cause mortality in the general population.

show abstract

Section: Discussionmentioning

confidence: 99%

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

336

291

View full text Add to dashboard Cite

show abstract

“…Establishing relevant biomarkers with prognostic significance may prove crucial in reducing the recurrence rate and modifying therapeutic strategies for individual DTC patients (4). To date, few molecular prognostic indicators have been used to evaluate the efficiency of DTC patient diagnosis and prognosis (5,6).…”

Section: Introductionmentioning

confidence: 99%

Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma

et al. 2011

View full text Add to dashboard Cite

Abstract. DEP domain containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR), a recently identified mTOR-interacting protein, is a novel candidate oncogene. Previous studies reveal that high DEPTOR expression is required to maintain PI3K and Akt activation and to inhibit apoptosis. However, its significance in differentiated thyroid carcinoma (DTC) is not yet known. The present study verifies the mRNA and protein expression of DEPTOR in five cell lines, DTC tissues and normal adjacent tissues. Tissue microarrays of 114 DTC patients were used to detect DEPTOR protein expression. The assessment of DEPTOR levels demonstrated that DEPTOR in DTC cells and tissues was significantly increased compared with normal cells and adjacent normal tissues. DEPTOR protein expression was significantly associated with lymph node status, extrathyroid extension and distant metastasis. Patients exhibiting high DEPTOR expression were statistically susceptible to earlier recurrence and poorer survival than those with low expression. Univariate and multivariate analyses showed that DEPTOR expression was an independent prognostic factor for DTC recurrence. In conclusion, our data indicate DEPTOR as a novel prognostic marker for DTC. IntroductionDifferentiated thyroid carcinoma (DTC) is the most common histological type of thyroid malignancy and its incidence is increasing (1). Although the majority of DTCs have a relative low mortality, with 10-year survival rates of 83-95%, approximately 30% of patients with DTC still undergo recurrence during the decades following initial therapy during several decades (2,3). Establishing relevant biomarkers with prognostic significance may prove crucial in reducing the recurrence rate and modifying therapeutic strategies for individual DTC patients (4). To date, few molecular prognostic indicators have been used to evaluate the efficiency of DTC patient diagnosis and prognosis (5,6).DEP domain containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR), a recently identified 48 kDa mTOR-interacting protein, is a novel candidate oncogene (7). DEPTOR is capable of inhibiting mTORC1 signaling and activation of mTORC2 signaling (8-10). As the downstream signal of DEPTOR, mTORC2 protein complex displays PDK-2 activity leading to serine 473 phosphorylation and overactivation of the PI3K/Akt pathway (11,12). Many key functions of PI3K/Akt signaling, such as genetic mutations of kinases and regulatory proteins, epigenetic alterations and post-translational modifications, have already been confirmed by in vitro studies and clinical data in thyroid cancer and a wide variety of other tumors (13-15). The significant role of DEPTOR in regulating tumor growth and progression indicates that it may closely correlate with aggressive clinical behaviors of DTC.However, the expression level of DEPTOR in DTC is largely unknown and the role of DEPTOR in clinical progression remains to be established. Therefore, we evaluated DEPTOR expression on the mRNA and protein level in thyroid ca...

show abstract

“…Galectin-3, a protein which bonds to β-galactoside residues of glycoproteins on the cell surface, is also defined in cytoplasmic and nuclear compartments (8,9). Galectin-3 expression has been reported to be a valuable marker for distinguishing between benign and malignant thyroid nodules.…”

Section: Discussionmentioning

confidence: 99%

Serum Galectin-3: diagnostic value for papillary thyroid carcinoma

Yılmaz¹,

Karsidag²,

Tatar³

et al. 2015

UCD

View full text Add to dashboard Cite

Objective: Thyroid cancer constitutes approximately 1% of all cancers, approximately 90% of the endocrine malignancies, and is responsible for 0.4% of cancer-related deaths. Additional markers are required for the accurate diagnosis of thyroid malignancies. There is no marker that can accurately facilitate pre-operative benign-malignant differentiation of thyroid nodules. The present study aims to evaluate the diagnostic value of preoperative serum Galectin-3 levels in thyroid cancer and to avoid unnecessary aggressive interventions. Material and Methods:Sixty-four patients who were operated between May 2009 and April 2011 were included in this study prospectively. Patients with toxic nodules and those with malignancies detected in preoperative fine needle aspiration biopsies (FNAB) were excluded. Patients with thyroid nodules of >3 cm in ultrasonography or having suspicious cytological findings in their preoperative FNABs regardless of the nodule size were included. Patients were divided into 2 groups, "control"and "cancer," according to the postoperative pathology results. Results:The control group included 50 and cancer group included 14 patients. The mean age of the control group was 44.84±13

show abstract

Diagnostic Utility of Galectin-3 in Thyroid Cancer

Cited by 135 publications

References 122 publications

The fibrosis marker galectin‐3 and outcome in the general population

The fibrosis marker galectin‐3 and outcome in the general population

Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma

Serum Galectin-3: diagnostic value for papillary thyroid carcinoma

Contact Info

Product

Resources

About